Fungizone
Polyene Antifungal for Severe Systemic Fungal Infections
Quick Facts About Fungizone
Key Takeaways About Fungizone
- Reserved for life-threatening infections: Fungizone is used only for severe systemic fungal infections that cannot be treated with safer alternatives; it is administered exclusively in hospital settings under close medical supervision
- Significant kidney toxicity: Nephrotoxicity is the most clinically important adverse effect; kidney function and electrolytes (especially potassium and magnesium) must be monitored throughout treatment
- Infusion-related reactions are common: Fever, chills, nausea, and vomiting frequently occur during the first days of treatment but typically diminish with continued therapy; premedication can help manage these symptoms
- Maximum daily dose is critical: The total daily dose must never exceed 1.5 mg/kg body weight, as overdose can cause fatal cardiac or respiratory arrest
- Liposomal formulations offer reduced toxicity: Lipid-based amphotericin B products (such as AmBisome) cause fewer side effects but are more expensive; your doctor will choose the appropriate formulation for your situation
What Is Fungizone and What Is It Used For?
Fungizone is the brand name for conventional (deoxycholate) amphotericin B, a potent antifungal antibiotic used to treat severe, life-threatening systemic fungal infections. It works by binding to ergosterol in fungal cell membranes, creating pores that cause leakage of cell contents and ultimately fungal cell death.
Amphotericin B, the active ingredient in Fungizone, belongs to the polyene class of antifungal agents. First isolated in 1955 from the soil bacterium Streptomyces nodosus, it has remained a cornerstone of antifungal therapy for more than six decades. Despite the introduction of newer antifungal classes – including azoles (fluconazole, voriconazole) and echinocandins (caspofungin, micafungin) – amphotericin B retains an important role in clinical practice due to its broad spectrum of activity and its effectiveness against many resistant fungal species.
Fungizone is indicated for the treatment of serious, potentially life-threatening fungal infections in tissues or internal organs. These include:
- Invasive aspergillosis – a severe infection caused by Aspergillus species, most commonly affecting the lungs in immunocompromised patients
- Systemic candidiasis – bloodstream and deep-seated infections caused by Candida species, including candidaemia and hepatosplenic candidiasis
- Cryptococcosis – infections caused by Cryptococcus neoformans, including cryptococcal meningitis, which is particularly common in patients with HIV/AIDS
- Histoplasmosis – a systemic infection caused by Histoplasma capsulatum, endemic in certain regions of the Americas and other tropical areas
- Coccidioidomycosis – also known as Valley fever, caused by Coccidioides species, endemic to the southwestern United States, Mexico, and parts of Central and South America
- Blastomycosis – caused by Blastomyces dermatitidis, found in North and South America
- South American leishmaniasis – a parasitic infection for which amphotericin B can be used as an alternative treatment
The mechanism of action of amphotericin B is unique among antifungal drugs. It binds preferentially to ergosterol, the principal sterol component of fungal cell membranes (analogous to cholesterol in human cell membranes). This binding creates transmembrane channels or pores that disrupt the permeability of the fungal cell membrane. As a result, essential intracellular components – including potassium ions, sugars, and amino acids – leak out of the cell, leading to cell death. Amphotericin B is considered fungicidal (kills fungi) rather than merely fungistatic (inhibits growth), which is an important advantage in treating severe infections in immunocompromised patients.
In addition to its direct antifungal activity, amphotericin B has immunomodulatory properties that can enhance the host immune response to fungal infections. It stimulates macrophage and T-cell function, which may contribute to its clinical efficacy, particularly in patients with weakened immune systems.
Amphotericin B is included on the World Health Organization's List of Essential Medicines, reflecting its critical importance in global healthcare. It remains the only polyene antifungal available for systemic use and is often referred to as the "gold standard" for antifungal therapy, particularly for severe infections in resource-limited settings where newer, more expensive alternatives may not be available.
What Should You Know Before Receiving Fungizone?
Before treatment with Fungizone, your doctor will evaluate your kidney function, liver function, and electrolyte levels. Fungizone is contraindicated only in patients with known hypersensitivity to amphotericin B, but several important precautions must be considered.
Contraindications
You should not receive Fungizone if:
- You are allergic to amphotericin B or to any of the other ingredients in this medicine, including sodium deoxycholate, sodium dihydrogen phosphate dihydrate, or disodium phosphate dodecahydrate
Because Fungizone is reserved for potentially life-threatening infections, there are very few absolute contraindications. In most cases, the severity of the underlying infection justifies the risks associated with treatment. However, your doctor will carefully weigh the benefits against the risks before initiating therapy.
Warnings and Precautions
Talk to your doctor or nurse before receiving Fungizone, especially if you have:
- Impaired kidney function – amphotericin B is nephrotoxic (damaging to the kidneys), and pre-existing kidney disease significantly increases the risk of further kidney damage. Your doctor will monitor kidney function closely throughout treatment by measuring serum creatinine, blood urea nitrogen (BUN), and creatinine clearance
- Electrolyte imbalances – Fungizone commonly causes loss of potassium (hypokalaemia) and magnesium (hypomagnesaemia) through the kidneys. These electrolytes will be monitored regularly, and supplementation may be required to prevent dangerous imbalances that could affect heart rhythm
- Liver disease – liver function tests may be affected during treatment, and your doctor will monitor liver enzymes regularly
- Heart conditions – electrolyte imbalances caused by Fungizone can affect heart rhythm, so patients with pre-existing cardiac conditions require additional monitoring
Your medical team will regularly test your blood to monitor kidney function, liver function, complete blood count, and serum electrolyte levels (particularly potassium and magnesium) throughout the course of treatment. Adequate hydration with intravenous normal saline before each infusion has been shown to reduce the risk of nephrotoxicity and is considered standard practice.
The total daily dose of Fungizone must never exceed 1.5 mg/kg body weight. Overdose above this threshold can cause fatal cardiac arrest or respiratory arrest. Treatment is always initiated at a low dose and gradually increased to the target dose over several days.
Drug Interactions
Tell your doctor about all medicines you are currently taking, have recently taken, or might take, as Fungizone can interact with several other medications. The most important interactions include:
- Corticosteroids and corticotropin (ACTH) – may worsen the potassium-lowering effect of amphotericin B, increasing the risk of dangerous hypokalaemia
- Digitalis glycosides (such as digoxin) – low potassium levels caused by Fungizone can increase the toxicity of these heart medications, potentially causing life-threatening cardiac arrhythmias
- Flucytosine – another antifungal sometimes used in combination with amphotericin B; the combination can increase flucytosine toxicity because amphotericin B-induced kidney impairment reduces flucytosine elimination
- Skeletal muscle relaxants (such as tubocurarine) – low potassium levels can enhance the effect of these drugs, potentially prolonging muscle paralysis during surgery
- Other nephrotoxic drugs – concurrent use with aminoglycosides (gentamicin, tobramycin), ciclosporin, tacrolimus, vancomycin, or non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of kidney damage
White blood cell transfusions should be separated from Fungizone infusions by as long an interval as possible. Acute lung reactions have been reported in patients who received intravenous amphotericin B simultaneously with or shortly after transfusion of white blood cells (leukocytes). Lung function should be monitored in these patients.
Pregnancy and Breastfeeding
Experience with the use of Fungizone during pregnancy is limited. Animal studies have not shown direct evidence of teratogenicity (birth defects), but the drug should only be used during pregnancy when the potential benefit to the mother clearly outweighs the potential risk to the foetus. In practice, this typically means when a pregnant woman has a life-threatening fungal infection for which no safer alternative exists.
It is unknown whether amphotericin B passes into breast milk. Given the seriousness of the infections for which Fungizone is used and the potential for adverse effects in the nursing infant, a decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the treatment to the mother. Consult your doctor before breastfeeding during treatment with Fungizone.
Driving and Operating Machinery
No specific studies have been conducted on the effects of Fungizone on the ability to drive or use machines. However, some side effects – including dizziness, blurred vision, and double vision – may impair your ability to drive or operate machinery safely. Since Fungizone is administered in a hospital setting, this is primarily relevant during recovery or after discharge. You should not drive or operate dangerous machinery if you experience any of these effects.
Sodium Content
This medicine contains less than 1 mmol (23 mg) sodium per vial, which means it is essentially sodium-free.
How Does Fungizone Interact with Other Drugs?
Fungizone can interact with many medications, particularly those that affect kidney function or potassium levels. The most clinically important interactions involve nephrotoxic drugs, corticosteroids, cardiac glycosides, and other antifungals. Always inform your medical team of all medications you are receiving.
Amphotericin B is primarily eliminated through non-renal mechanisms and has a very long terminal half-life (approximately 15 days). It is not significantly metabolised by the cytochrome P450 enzyme system, so drug interactions are primarily based on pharmacodynamic effects (additive toxicity) rather than altered drug metabolism. The two principal concerns are additive nephrotoxicity and enhanced hypokalaemia.
Major Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Aminoglycosides (gentamicin, tobramycin) | Antibiotics | Additive nephrotoxicity; significantly increased risk of acute kidney injury | Avoid concurrent use if possible; monitor kidney function daily |
| Ciclosporin / Tacrolimus | Immunosuppressants | Additive nephrotoxicity; increased risk of severe kidney impairment | Monitor kidney function and drug levels closely; dose adjustment may be needed |
| Digitalis glycosides (digoxin) | Cardiac glycosides | Amphotericin-induced hypokalaemia potentiates digoxin toxicity, risking fatal arrhythmias | Monitor potassium levels closely; supplement potassium as needed |
| Corticosteroids / ACTH | Anti-inflammatory / Hormones | Potentiate potassium depletion; can cause severe hypokalaemia | Monitor electrolytes frequently; avoid long-term concurrent use |
| Flucytosine | Antifungal | Amphotericin B-induced kidney impairment reduces flucytosine clearance, increasing its toxicity (bone marrow suppression) | Monitor flucytosine levels and blood counts; adjust flucytosine dose based on kidney function |
Other Clinically Relevant Interactions
| Drug | Category | Effect | Recommendation |
|---|---|---|---|
| Skeletal muscle relaxants | Anaesthetic agents | Hypokalaemia enhances neuromuscular blockade, potentially prolonging paralysis | Check potassium levels before surgery; correct any deficiency |
| Vancomycin | Glycopeptide antibiotic | Additive nephrotoxicity | Monitor kidney function closely when used concurrently |
| Diuretics (furosemide, thiazides) | Diuretics | May potentiate electrolyte imbalances, particularly hypokalaemia | Monitor electrolytes closely and supplement as needed |
| White blood cell transfusions | Blood products | Acute pulmonary reactions (dyspnoea, hypoxaemia) reported when given concurrently | Separate infusions by as long an interval as possible; monitor lung function |
Fungizone must never be mixed with sodium chloride (normal saline) solution or any solution containing preservatives such as benzyl alcohol, as these cause immediate precipitation of the drug. It must only be diluted in 5% glucose (dextrose) solution with a pH above 4.2. No other medications should be added to the amphotericin B infusion solution.
What Is the Correct Dosage of Fungizone?
Fungizone dosing is highly individualised and must be determined by a specialist physician. Treatment begins with a small test dose, followed by gradual escalation to a target dose of 0.25–1.0 mg/kg/day, given as an intravenous infusion over 1–6 hours. The maximum daily dose must never exceed 1.5 mg/kg.
Because individual tolerance to amphotericin B varies considerably, dosing must be carefully tailored to each patient. Fungizone is always administered in a hospital setting by experienced healthcare professionals, and the drug is given as an intravenous infusion (drip) through a central venous catheter. The infusion typically takes between 1 and 6 hours, depending on the dose and the patient's tolerance.
Test Dose
Before starting full treatment, a test dose is usually given to assess tolerance. This involves infusing 1 to 5 mg of amphotericin B dissolved in 20 mL of 5% glucose solution over 20–30 minutes. During and after the test dose, vital signs – including temperature, pulse, blood pressure, and respiratory rate – are monitored for 2–4 hours. In patients with impaired cardiac function or unstable circulation, the lower test dose (1 mg) is preferred. Alternatively, the test dose may be replaced by a slow initial infusion at a low dose.
Adults
Standard Adult Dosing
Initial dose: 0.25 mg/kg body weight per day, given as a single intravenous infusion.
Dose escalation: The dose is increased by 5–10 mg per day until the target maintenance dose is reached, typically up to 1.0 mg/kg/day. In patients with more severe infections, dose escalation to the full dose should be completed within 2–3 days.
Maximum dose: Must not exceed 1.5 mg/kg/day under any circumstances.
Alternate-day dosing: Once clinical improvement is observed, administration may be switched to every other day if toxicity is a concern. Note that alternate-day dosing is not sufficiently documented for aspergillosis or non-albicans Candida infections.
Duration of treatment: Depends on the type and severity of infection and the patient's immune status. Deep-seated mycoses may require 6–12 weeks or longer. Transition to oral antifungal therapy (such as fluconazole, voriconazole, or itraconazole) should be considered once the infection and the patient's condition have stabilised or improved.
Children
Paediatric Dosing
The dosing principles for children are similar to those for adults, with doses calculated on a mg/kg body weight basis. However, paediatric dosing requires additional specialist supervision. The test dose, dose escalation, and maximum dose (1.5 mg/kg/day) guidelines apply equally to paediatric patients. Paediatric infectious disease specialists should be involved in treatment decisions.
Elderly Patients
Elderly Dosing
No specific dose adjustment is recommended for elderly patients. However, older adults are more susceptible to nephrotoxicity and electrolyte disturbances, so more frequent monitoring is advisable. Pre-existing renal impairment, which is more common in elderly patients, may necessitate slower dose escalation and lower target doses.
Patients with Kidney Impairment
Renal Dose Adjustments
There are no specific formal dose adjustments published for renal impairment. However, in practice, the dosage should be kept at the lowest effective level, and kidney function should be monitored with increased frequency. If serum creatinine rises significantly during treatment, the dose may be reduced or dosing frequency decreased (e.g., alternate-day administration). In some cases, temporary discontinuation may be necessary to allow kidney function to recover before resuming therapy.
Preparation of Infusion Solution
The reconstitution and preparation of Fungizone infusion solutions must be performed under aseptic conditions by qualified personnel, typically in a hospital pharmacy:
- Reconstitution: Add 10 mL of sterile water for injection (without preservatives) to the vial containing 50 mg amphotericin B powder. Shake until the solution is clear, producing a concentrate of 5 mg/mL.
- Dilution: Dilute the required volume of concentrate in 5% glucose infusion solution to a final concentration of no more than 0.1 mg/mL. The glucose solution must have a pH above 4.2.
- pH adjustment: If the pH of the glucose solution is below 4.2, a phosphate buffer solution should be added (1–2 mL per litre of glucose solution) before diluting the concentrate.
Never reconstitute or dilute Fungizone with sodium chloride (saline) solution or any solution containing bacteriostatic agents (such as benzyl alcohol), as these cause immediate precipitation. If an in-line membrane filter is used during infusion, the pore diameter must be at least 1 micrometre to allow the colloidal particles to pass through.
Overdose
Amphotericin B overdose is a medical emergency. Overdose beyond the maximum daily dose of 1.5 mg/kg can result in cardiac arrest or respiratory arrest with potentially fatal outcomes. If an overdose is suspected, the infusion must be stopped immediately and the patient must receive intensive supportive care. There is no specific antidote for amphotericin B. Contact your local poison control centre for guidance.
What Are the Side Effects of Fungizone?
Like all medicines, Fungizone can cause side effects, although not everybody experiences them. The most common side effects are infusion-related reactions (fever, chills, nausea, vomiting), kidney toxicity, and electrolyte disturbances. These typically improve with continued treatment and can often be managed with supportive medications.
Amphotericin B is associated with a wide range of side effects, reflecting its binding to cholesterol in human cell membranes as well as to ergosterol in fungal membranes. The most clinically significant adverse effects involve the kidneys (nephrotoxicity) and infusion-related reactions. Understanding these side effects is essential for both patients and healthcare providers to ensure optimal management during treatment.
Serious Side Effects
Seek immediate medical attention if you experience any of the following:
- Severe skin reactions – Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Symptoms include a spreading rash with or without blisters, redness, sores or swelling in the mouth, throat, eyes, nose and around the genitals, accompanied by fever and flu-like symptoms. These are potentially life-threatening conditions requiring immediate medical care.
- Serious allergic reactions (anaphylaxis) – symptoms include rash, difficulty swallowing or breathing, and swelling of the lips, face, throat, or tongue. These reactions require emergency treatment.
Side Effects by Frequency
Very Common
May affect more than 1 in 10 people
- Nausea and vomiting
- Fever and chills
- Low potassium levels (hypokalaemia)
- Elevated serum creatinine (indicating kidney stress)
- Abnormal kidney function tests
- Shortness of breath (dyspnoea)
- Low blood pressure (hypotension)
Common
May affect up to 1 in 10 people
- Anaemia (low red blood cells)
- Liver function disturbances
- Low magnesium levels (hypomagnesaemia)
- Skin rash
Uncommon
May affect up to 1 in 100 people
- Facial and neck flushing
Reported (Frequency Unknown)
Frequency cannot be estimated from available data
- Changes in blood cell counts (white blood cells, platelets)
- Cardiac arrhythmias, cardiac arrest, heart failure
- Hearing loss, tinnitus (ringing in ears), dizziness
- Blurred vision, double vision
- Gastrointestinal bleeding, upper abdominal pain, diarrhoea, blood in stool
- Acute liver failure, jaundice (yellowing of skin and eyes)
- High potassium levels (hyperkalaemia), weight loss, appetite loss
- Joint and muscle pain, cramps
- Seizures, headache, brain damage, nerve damage
- Acute kidney failure, inability to urinate, nephrogenic diabetes insipidus
- Lung inflammation, bronchospasm, pulmonary oedema
- Itching, skin peeling
- High blood pressure, shock
- Pain and inflammation at the injection site, thrombophlebitis
Managing Infusion-Related Reactions
Fever, chills, headache, muscle and/or joint pain, decreased appetite, nausea, vomiting, and low blood pressure are common during the first few days of treatment, but these symptoms typically diminish with continued therapy. Your medical team may use several strategies to reduce these reactions:
- Paracetamol (acetaminophen) or other analgesics and antipyretics to reduce fever and pain
- Antiemetics (anti-nausea medications) to control nausea and vomiting
- Antihistamines (such as diphenhydramine) to reduce allergic-type reactions
- Hydrocortisone as premedication before the infusion in some protocols
- Intravenous saline loading (500–1000 mL normal saline) before each infusion to protect the kidneys
- Electrolyte supplementation with potassium and magnesium as determined by blood tests
Kidney function disturbances are also common but typically improve when treatment is discontinued. However, prolonged therapy or high cumulative doses may cause permanent nephron damage. Local reactions at the injection site, including pain and inflammation of the blood vessel (thrombophlebitis), are also frequently reported.
How Should Fungizone Be Stored?
Fungizone powder must be stored in a refrigerator (2–8°C), protected from light, in its original packaging. Reconstituted concentrate can be kept for up to 24 hours refrigerated, and the final infusion solution should be used within 8 hours of preparation.
Proper storage of Fungizone is essential to maintain its efficacy and safety. The drug is light-sensitive, meaning exposure to light can cause degradation of the active ingredient. The following storage conditions must be observed:
| Form | Storage Temperature | Shelf Life | Special Instructions |
|---|---|---|---|
| Powder (unopened vial) | 2–8°C (refrigerator) | Until expiry date on packaging | Keep in original packaging; protect from light |
| Reconstituted concentrate (5 mg/mL) | 2–8°C (refrigerator) | 24 hours | Discard any unused concentrate after 24 hours |
| Final infusion solution | Room temperature | Use within 8 hours | Use immediately after preparation; protect from light during infusion |
Keep this medicine out of the sight and reach of children. Do not use Fungizone after the expiry date stated on the packaging (EXP). The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
If the reconstituted concentrate or the final infusion solution shows any signs of precipitation, cloudiness, or foreign particles, the solution must be discarded and not administered to the patient.
What Does Fungizone Contain?
Each vial of Fungizone contains 50 mg of amphotericin B as the active ingredient, along with sodium deoxycholate (a surfactant that forms the drug into a colloidal dispersion) and phosphate buffer salts. The product is a yellow powder that forms a clear solution when reconstituted.
Active Ingredient
The active substance is amphotericin B. Each glass injection vial contains 50 mg of amphotericin B.
Other Ingredients (Excipients)
- Sodium deoxycholate – a bile salt surfactant that forms a colloidal dispersion with amphotericin B, allowing the poorly water-soluble drug to be administered intravenously
- Sodium dihydrogen phosphate dihydrate – a buffer salt used to maintain the pH of the solution
- Disodium phosphate dodecahydrate – a buffer salt used in combination with sodium dihydrogen phosphate
Appearance and Pack Size
Fungizone powder for solution for infusion is a yellow powder. When correctly reconstituted, it forms a clear solution. The medicine is supplied in glass injection vials, with a pack size of 1 × 50 mg vial.
Manufacturer and Marketing Authorisation Holder
Marketing Authorisation Holder: CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 24, 17489 Greifswald, Germany.
Manufacturer: Delpharm Saint Remy, Rue de l'Isle, Saint-Remy-Sur-Avre, 28380, France.
Frequently Asked Questions About Fungizone
Fungizone is the conventional (deoxycholate) formulation of amphotericin B, while AmBisome is a liposomal formulation in which the drug is encapsulated in small lipid vesicles (liposomes). The key difference is in tolerability: liposomal amphotericin B causes significantly less kidney toxicity and fewer infusion-related side effects. Clinical guidelines from the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) generally recommend lipid-based formulations when available, particularly for patients at high risk of nephrotoxicity. However, Fungizone remains widely used in many countries due to its significantly lower cost and established efficacy.
Amphotericin B causes nephrotoxicity through two main mechanisms. First, it causes vasoconstriction (narrowing) of the afferent arterioles in the kidneys, which reduces renal blood flow and the glomerular filtration rate. Second, its binding to cholesterol in the cell membranes of renal tubular cells creates pores that damage these cells directly, impairing the kidney's ability to concentrate urine and regulate electrolytes. This results in loss of potassium and magnesium in the urine. Strategies to reduce nephrotoxicity include adequate hydration with intravenous saline before each infusion, avoiding concurrent nephrotoxic medications, and using the lowest effective dose.
Fungizone should only be administered in a hospital setting or under close medical supervision. This is because of the risk of severe infusion-related reactions (including anaphylaxis), the need for continuous monitoring of vital signs during and after infusion, and the requirement for regular blood tests to assess kidney function and electrolytes. The drug must be prepared under aseptic conditions by qualified personnel, and it is given through a central venous catheter with infusion rates carefully controlled over 1–6 hours. In some specialised centres, experienced patients on stable doses may receive later doses through outpatient infusion services, but this is always under medical supervision.
The duration of treatment depends on the type and severity of the infection, as well as the patient's immune status and response to therapy. Deep-seated mycoses (such as invasive aspergillosis or disseminated candidiasis) may require 6–12 weeks or longer of treatment. In some cases, the initial course of intravenous amphotericin B is followed by a switch to oral antifungal therapy (step-down therapy) once the patient's condition has stabilised and improved. Cryptococcal meningitis in HIV-positive patients, for example, typically involves an initial 2-week induction phase with amphotericin B followed by long-term oral fluconazole maintenance therapy.
Amphotericin B has one of the broadest spectrums of any antifungal agent, but it is not active against all fungi. It is highly effective against most Candida species (though some, such as C. lusitaniae, may be resistant), Aspergillus species, Cryptococcus neoformans, Histoplasma, Blastomyces, Coccidioides, and many other dimorphic and filamentous fungi. However, it has limited or no activity against certain species including Aspergillus terreus, Scedosporium apiospermum, and Fusarium species. Additionally, some moulds like Mucor and Rhizopus (causing mucormycosis) remain susceptible to amphotericin B, making it a key treatment option for these dangerous infections.
Comprehensive monitoring is essential throughout treatment with Fungizone. This includes: kidney function (serum creatinine, BUN, and creatinine clearance) – typically measured daily during dose escalation and at least twice weekly during maintenance therapy; serum electrolytes (especially potassium and magnesium) – monitored frequently with supplementation as needed; complete blood count (haemoglobin, white blood cells, and platelets); liver function tests (ALT, AST, bilirubin); and vital signs during and for several hours after each infusion. Patients also require careful clinical assessment for signs of toxicity, including changes in urine output, hearing changes, and neurological symptoms.
References
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
- Hamill RJ. Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity. Drugs. 2013;73(9):919–934. doi:10.1007/s40265-013-0069-4
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50. doi:10.1093/cid/civ933
- Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
- Perfect JR, Dismukes WE, Dromer F, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322. doi:10.1086/649858
- Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Rev Iberoam Micol. 2009;26(4):223–227. doi:10.1016/j.riam.2009.06.003
- Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother. 2002;49(Suppl 1):37–41. doi:10.1093/jac/49.suppl_1.37
- Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37. doi:10.1111/1469-0691.12039
- European Medicines Agency. Summary of Product Characteristics: Amphotericin B. EMA; 2024.
- British National Formulary (BNF). Amphotericin B (intravenous). NICE; 2025. Available at: bnf.nice.org.uk
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes specialists in infectious disease, clinical microbiology, clinical pharmacology, and internal medicine.
Written by licensed physicians with expertise in infectious disease pharmacotherapy, following WHO, IDSA, and ESCMID guidelines. All content is evidence-based and adheres to the GRADE framework for evaluating the quality of evidence.
Reviewed by the iMedic Medical Review Board – an independent panel of specialists who verify the clinical accuracy, completeness, and currency of all published content. Last reviewed: .
Conflict of Interest Statement: The iMedic Medical Editorial Team declares no conflicts of interest. iMedic receives no commercial funding or pharmaceutical sponsorship. All content is produced independently.